Search Results | Diabetes Care | American Diabetes Association

1-20 of 204

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes

Diabetes Care 2022;45(6):1416–1427

DOI: https://doi.org/10.2337/dc21-2204

Published: 04 April 2022

View article

Journal Articles

Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials

Huilin Tang, Stephen E. Kimmel, Steven M. Smith, Kenneth Cusi, Weilong Shi, Matthew Gurka, Almut G. Winterstein, Jingchuan Guo

Diabetes Care 2022;45(4):1007–1012

DOI: https://doi.org/10.2337/dc21-1722

Published: 29 March 2022

View article

Journal Articles

Association of Longitudinal Trajectories of Insulin Resistance With Adverse Renal Outcomes

Seokhun Yang, Soongu Kwak, You-Hyun Song, Seung Seok Han, Hye Sun Lee, Shinae Kang, Seung-Pyo Lee

Diabetes Care 2022;45(5):1268–1275

DOI: https://doi.org/10.2337/dc21-2521

Published: 15 March 2022

View article

Journal Articles

Comment on Oosterwijk et al. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. Diabetes Care 2022;45:35–41

Samuel N. Heyman, Itamar Raz, Zaid Abassi

Diabetes Care 2022;45(3):e67–e68

DOI: https://doi.org/10.2337/dc21-2393

Published: 04 March 2022

View article

Journal Articles

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA_1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Peter Rossing, Ellen Burgess, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Pieter Gillard, Richard J. MacIsaac, Julio Wainstein, Amer Joseph, Meike Brinker, Lothar Roessig, Charlie Scott, George L. Bakris

Diabetes Care 2022;45(4):888–897

DOI: https://doi.org/10.2337/dc21-1944

Published: 21 January 2022

View article

Journal Articles

Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes

Juraj Koska, Hertzel C. Gerstein, Paul J. Beisswenger, Peter D. Reaven

Diabetes Care 2022;45(3):684–691

DOI: https://doi.org/10.2337/dc21-2196

Published: 20 January 2022

View article

Journal Articles

Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes

Bruce A. Perkins, Ionut Bebu, Xiaoyu Gao, Amy B. Karger, Irl B. Hirsch, Harsha Karanchi, Mark E. Molitch, Bernard Zinman, John M. Lachin, Ian H. de Boer

Diabetes Care 2022;45(3):585–593

DOI: https://doi.org/10.2337/dc21-1883

Published: 11 January 2022

View article

Journal Articles

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

Diabetes Care 2022;45(4):938–946

DOI: https://doi.org/10.2337/dc21-1744

Published: 11 January 2022

View article

Journal Articles

Comment on Stempniewicz et al. Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Diabetes Care 2021;44:2000–2009

Jonah Mink, Raj Thakkar, Danielle Jeddah

Diabetes Care 2022;45(1):e19–e20

DOI: https://doi.org/10.2337/dc21-2005

Published: 28 December 2021

View article

Journal Articles

11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022

American Diabetes Association Professional Practice Committee

Diabetes Care 2022;45(Supplement_1):S175–S184

DOI: https://doi.org/10.2337/dc22-S011

Published: 16 December 2021

View article

Journal Articles

Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database

Diabetes Care 2021;44(11):2542–2551

DOI: https://doi.org/10.2337/dc21-1081

Published: 18 October 2021

View article

Journal Articles

Effects of Metabolic Factors, Race-Ethnicity, and Sex on the Development of Nephropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study

TODAY Study Group

Diabetes Care 2022;45(5):1056–1064

DOI: https://doi.org/10.2337/dc21-1085

Published: 16 September 2021

View article

Journal Articles

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Diabetes Care 2021;44(8):1805–1815

DOI: https://doi.org/10.2337/dc21-0076

Published: 11 August 2021

View article

Journal Articles

Issues and Events

Diabetes Care 2021;44(7):1726

DOI: https://doi.org/10.2337/dc21-ie07

Published: 20 July 2021

View article

Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Frederik Persson, Peter Rossing, Priya Vart, Glenn M. Chertow, Fan Fan Hou, Niels Jongs, John J.V. McMurray, Ricardo Correa-Rotter, Harpreet S. Bajaj, Bergur V. Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink

Diabetes Care 2021;44(8):1894–1897

DOI: https://doi.org/10.2337/dc21-0300

Published: 28 June 2021

View article

Journal Articles

Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015

Ian J. Neeland, Takatoshi Kasai, Silvio E. Inzucchi, Brian S. Wojeck, Henry K. Yaggi, Odd Erik Johansen

Diabetes Care 2021;44(6):e137–e138

DOI: https://doi.org/10.2337/dci21-0009

Published: 18 June 2021

View article

Journal Articles

Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015

Shay Brikman, Guy Dori

Diabetes Care 2021;44(6):e136

DOI: https://doi.org/10.2337/dc21-0310

Published: 18 June 2021

View article

Journal Articles

Issues and Events

Diabetes Care 2021;44(6):1458

DOI: https://doi.org/10.2337/dc21-ie06

Published: 18 June 2021

View article

Journal Articles

Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S125–S150

Diabetes Care 2021;44(9):2183–2185

DOI: https://doi.org/10.2337/dc21-ad09a

Published: 16 June 2021

View article

Journal Articles

ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes

Yawa Abouleka, Kamel Mohammedi, Charlyne Carpentier, Severine Dubois, Pierre Gourdy, Jean-François Gautier, Ronan Roussel, André Scheen, François Alhenc-Gelas, Samy Hadjadj, Gilberto Velho, Michel Marre

Diabetes Care 2021;44(6):1377–1384

DOI: https://doi.org/10.2337/dc20-3036

Published: 07 April 2021

View article

2 3 4 5

NARROW

Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes

Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials

Association of Longitudinal Trajectories of Insulin Resistance With Adverse Renal Outcomes

Comment on Oosterwijk et al. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. Diabetes Care 2022;45:35–41

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA_1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes

Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Comment on Stempniewicz et al. Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Diabetes Care 2021;44:2000–2009

11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022

Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database

Effects of Metabolic Factors, Race-Ethnicity, and Sex on the Development of Nephropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Issues and Events

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015

Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015

Issues and Events

Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S125–S150

ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only